Loading...
•
Jun 30, 2022
Teva Q2 2022 Earnings Report
Delivered solid performance despite macroeconomic headwinds and reached agreement in principle on nationwide opioids settlement
Key Takeaways
Teva reported Q2 2022 results with revenues of $3.8 billion. The company has reached an agreement in principle on a nationwide opioids settlement. The 2022 revenue outlook was revised due to foreign exchange headwinds and increased competition for COPAXONE, while reaffirming earnings and cash flow guidance.
Revenues of $3.8 billion
GAAP diluted loss per share of $0.21
Non-GAAP diluted EPS of $0.68
Free cash flow of $301 million
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Teva revised its 2022 revenues outlook mainly due to continued foreign exchange headwinds and increased competition and foreign exchange fluctuations. Operating income, EBITDA, EPS and free cash flow were reaffirmed.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...